PDC BIOTECH
PDC Biotech GmbH (PDC) is a private biopharmaceutical company developing innovative therapeutics for the treatment of preterm labour and primary dysmenorrhea, two areas of significant unmet medical need and large market potential. The primary focus for the company is the development of a pipeline of products which are antagonists of the receptor for prostaglandin F2α (FP receptor). PDC has licensed exclusive worldwide rights to a family of FP receptor antagonists from Theratechnologies Inc. (www.theratech.com) which include both peptides (compounds composed of at least two amino acids) and peptidomimetics (peptide-like compounds).
PDC BIOTECH
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.pdcbiotech.com
Total Employee:
1+
Status:
Active
Contact:
43 1 8900077
Email Addresses:
[email protected]
Total Funding:
5.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible GoDaddy DNS Google Google Cloud CloudFront OpenResty Google Adsense Google Cloud Global Multi-Region AdBlock Acceptable Ads
Founder
Investors List
Andera Partners
Andera Partners investment in Series A - PDC Biotech
MIG
MIG investment in Series A - PDC Biotech
Official Site Inspections
http://www.pdcbiotech.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 76.223.54.146
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "PDC Biotech"
Home - PDC Therapeutics
Targeted TherapiesWith no Compromise PDC Therapeutics is a clinical-stage biotechnology start-up developing smart nanomedicines for targeted therapies. Superior Therapeutic Index …See details»
PDS Biotechnology Reports Inducement Grant Under Nasdaq …
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company …See details»
PDS Biotech - News 2023
Nov 28, 2023 PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients worldwide. We are …See details»
PDS Biotech - PDS Biotech Announces Positive Clinical Data ...
Feb 26, 2025 For more information, please visit www.pdsbiotech.com Forward Looking Statements This communication contains forward-looking statements (including within the …See details»
PDS Biotech Leadership to Participate in March Conferences
Mar 11, 2025 For more information, please visit www.pdsbiotech.com. Forward Looking Statements This communication contains forward-looking statements (including within the …See details»
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to …
Aug 14, 2023 VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and neck cancer PDS Biotech anticipates …See details»
PDS Biotech Announces up to $22 Million Registered Direct …
Feb 27, 2025 $11 Million Upfront with up to an Additional $11 Million of Aggregate Gross Proceeds Upon the Cash Exercise in Full of the WarrantsPRINCETON, N.J., Feb. 27, 2025 …See details»
PDS Biotech Announces Circulating Tumor DNA Results for
Feb 24, 2025 PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer ResearchSee details»
PDS Biotech Announces FDA Clearance of IND Application for Combi
For more information, please visit www.pdsbiotech.com Forward Looking Statements This communication contains forward-looking statements (including within the meaning of Section …See details»
PDS Biotech and Farmacore Announce Blanver to Join
Feb 22, 2021 As the license holder of Versamune-CoV2-FC (PDS0203) in Latin America, Farmacore will continue to lead the regulatory and clinical trial efforts in Brazil and has …See details»
PDS Biotechnology Corporation Announces Closing of
FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy …See details»
PDS Biotech - PDS0101
PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients worldwide. We are also committed to …See details»
PDS Biotechnology Announces Conference Call and Webcast for …
Nov 14, 2023 To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech. Forward Looking Statements. This communication contains forward-looking …See details»
PDS Biotech Announces Expanded Interim Data in PDS0101
Oct 11, 2022 [email protected]. Rich Cockrell CG Capital Phone: +1 (404) 736-3838 [email protected]. Media Dave Schemelia Tiberend Strategic Advisors, Inc. Phone: +1 (609) …See details»
PDS Biotech Announces FDA Clearance of IND Application for
Mar 13, 2025 For more information, please visit www.pdsbiotech.com Forward Looking Statements This communication contains forward-looking statements (including within the …See details»
PDS Biotech Announces FDA Clearance of IND ... - Markets Insider
Mar 13, 2025 For more information, please visit www.pdsbiotech.com Forward Looking Statements This communication contains forward-looking statements (including within the …See details»
PDS Biotech Announces Circulating Tumor DNA Results for …
Feb 24, 2025 For more information, please visit www.pdsbiotech.com. Forward-Looking Statements This communication contains forward-looking statements (including within the …See details»
Establishing Canada’s first large-scale bioinnovation centre
3 days ago The Neptune BioInnovation Centre (NBC), a 51,000 sq ft facility on a 12.3 acre lot in Dartmouth, will offer leasable wet and dry lab space, warehouse and office spaces, and …See details»
PDS Biotech Announces Clinical Strategy Update and
Mar 27, 2024 Unique mechanism of action of the combination of PDS01ADC and Versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck …See details»
PDS Biotechnology Granted FDA Fast Track Designation for Lead …
To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech. Forward Looking Statements This communication contains forward-looking statements …See details»